State Street SPDR S&P Pharmaceuticals ETF
XPH
66 hedge funds and large institutions have $112M invested in State Street SPDR S&P Pharmaceuticals ETF in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 13 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
6% more capital invested
Capital invested by funds: $105M → $112M (+$6.08M)
0.92% less ownership
Funds ownership: 54.29% → 53.38% (-0.92%)
7% less funds holding
Funds holding: 71 → 66 (-5)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
100% less call options, than puts
Call options by funds: $2K | Put options by funds: $932K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$14.2M |
| 2 |
Morgan Stanley
New York
|
+$4.68M |
| 3 |
Goldman Sachs
New York
|
+$3.59M |
| 4 |
CI
CX Institutional
Auburn,
Indiana
|
+$3.36M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
-$4.71M |
| 2 |
JP Morgan Chase
New York
|
-$4.45M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$4.4M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.55M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.43M |
XPH Hedge Fund Activity: Q3 2022 in Review
66 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2022, worth a combined $112M — up 5.8% from $105M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of XPH and 9 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 23 added.
The largest buyer was Raymond James Financial Services Advisors, adding an estimated $14.2M. The largest seller was Clark Capital Management Group, exiting entirely with an estimated $4.71M sold.
- 66 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2022, down from 71 in Q2 2022.
- Funds reported $112M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2022, up 5.8% quarter-over-quarter.
- 9 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2022 and 13 closed out, a net change of -4 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2022 was Raymond James Financial Services Advisors, an estimated $14.2M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2022 was Clark Capital Management Group, an estimated $4.71M sold.
Based on aggregated 13F filings for Q3 2022.